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Fucoidan, a sulfated polysaccharide extracted from brown algae, has a wide range of biological activities, including anti-inflammatory, anti-
viral, and anti-tumor activities. In the present study, we investigated the effects of fucoidan on CCl4-induced liver fibrosis. Administration of
fucoidan reduced CCl4-induced acute and chronic liver failure. Hepatic fibrosis induced by CCl4 was also attenuated by injection of fucoidan.
Damage to hepatocytes and activation of hepatic stellate cells are key events in liver fibrosis, and, interestingly, treatment of hepatocytes with
fucoidan prevented CCl4-induced cell death and inhibited the proliferation hepatic stellate cells. These results indicate that fucoidan might be a
promising anti-fibrotic agent possessing dual functions, namely, protection of hepatocytes and inhibition of hepatic stellate cell proliferation.
© 2007 Elsevier B.V. Open access under CC BY license.Keywords: Fucoidan; Liver fibrosis; Hepatocyte; Hepatic stellate cell1. Introduction
Hepatic fibrosis results from chronic damage to the liver in
conjunction with the progressive accumulation of fibrillar
extracellular matrix proteins (Friedman, 1993; Gressner, 1995;
Lieber, 1999). The main causes of liver fibrosis are infection
with hepatitis B or C, alcohol abuse, and non-alcohol steato-
hepatitis. There are over 100 million people with hepatic
fibrosis in the world.
The liver consists of parenchymal (hepatocytes) and non-
parenchymal cells (Kupffer, stellate, and endothelial cells).
Hepatic fibrosis is triggered by specific intercellular interactions
among some of these cells. Kupffer cells are activated by
membrane components from damaged hepatocytes and infil-
trating inflammatory cells. The activated Kupffer cells release
pro-fibrotic factors, such as transforming growth factor-β,
reactive oxygen species, and other factors (Wu et al., 1998).
These pro-fibrotic factors act on hepatic stellate cells, which are
key players in hepatic fibrosis (Gressner, 1995).
Hepatic stellate cells are normally quiescent and produce
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Open access under CC BY license.laminin and collagen type IV, during the formation of basement
membrane (Maher and Bissell, 1993). Exposure of hepatic
stellate cells to the pro-fibrotic factors activates hepatic stellate
cells, leading to a changed to a myofibroblast phenotype and an
increase in the production of collagen (Friedman, 1999; Geerts,
2001). Preventing the activation of hepatic stellate cells is thus a
promising anti-fibrotic strategy. Indeed, administration of
antioxidants has been shown to suppress the activation of
hepatic stellate cells, thereby preventing liver fibrosis, and
inhibition of hepatocyte cell death can reduce liver fibrosis
(Houglum et al., 1997; Maher et al., 1997; Horie et al., 2003;
Canbay et al., 2002; Song et al., 2003).
Brown algae seaweeds contain both soluble dietary fiber
polysaccharides, including alginates, fucans, and laminarans,
and insoluble fibers, which are mostly composed of cellulose
(Lahaye and Kaeffer, 1997; Kloareg and Quatrano, 1988). The
fucans are cell wall polysaccharides that contain variable
amounts of fucose, uronic acids, galactose, xylose, and sulfate.
They are classified in three types according to their chemical
composition: fucoidan, ascophyllan, and glucuronofuco-galac-
tan sulfate (Lahaye and Kaeffer, 1997; Kloareg and Quatrano,
1988; Mabeau et al., 1990). Fucoidan is a complex sulfated
polysaccharide derived from Fucus vesiculosus, and it has a
variety of biological activities, including anti-inflammatory,
anti-viral, anti-liver failure, and anti-tumor activities (Boisson-
Vidal et al., 1995; Saito et al., 2006). Furthermore, fucoidan
Fig. 1. Effect of fucoidan on CCl4-induced hepatic injury. Mice received
intraperitoneal injection of CCl4 and intravenous injection of fucoidan. After
24 h, blood was recovered, and the serum AST (open column) and ALT (slashed
column) levels were determined using commercially available kits. Results
represent means±S.D. (n=4).
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idative properties (Xue et al., 2001; McCaffrey et al., 1994).
These findings indicate that fucoidan may have anti-fibrotic
activity, but whether fucoidan can attenuate hepatic fibrosis is
unknown. Therefore, in the present study, we evaluated the
effects of fucoidan on hepatic injury and fibrosis. We found that
fucoidan may be useful as a novel type of anti-fibrotic agent.
2. Materials and methods
2.1. Reagents
CCl4 was purchased from Wako Pure Chemicals, Co. Ltd.
(Osaka, Japan). Fucoidan was obtained from Sigma Chemical,
Co. Ltd. (St. Louis, MO). CCl4 and fucoidan were dissolved in
olive oil and saline in animal experiment, respectively. In
cellular experiments, fucoidan was dissolved in cultured
medium for hepatocytes or hepatic stellate cells as described
below. CCl4 was dissolved in dimethylsulfoxide at 100 mM.
2.2. Animals and experimental protocols
All of the experimental protocols conformed to the ethics
guidelines of the Graduate School of Pharmaceutical Sciences,
Osaka University. Male Sprague–Dawley rats (200–250 g) and
male ddy mice (6 weeks old) were obtained from SLC
(Shizuoka, Japan). The mice were housed in an environmentally
controlled room (lights on from 8:00 to 20:00; temperature, 23±
1.5 °C). Animals had free access to water and commercial chow
(Type MF, Oriental Yeast, Tokyo, Japan).
In the acute liver injury model, CCl4 was intraperitoneally
administrated to mice at 0.3 ml/kg body weight with or without
intravenous injection of fucoidan (25 and 50 mg/kg body
weight). After 24 h of fucoidan injection, the mice were
anesthetized, and the blood was recovered. In the chronic liver
injury model, CCl4 (0.3 ml/kg body weight) and fucoidan
(50 mg/kg body weight) were administered orally and
intravenously, respectively, to mice twice a week for 8 weeks.
The liver and blood were recovered from the mice under
anesthesia. The serum was separated from the blood and stored
at −20 °C before assay.
2.3. Aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) assays
Serum AST and ALT levels were measured using commer-
cially available kits (Mitsubishi Kagaku Iatron Inc., Tokyo,
Japan) according to the manufacturer's instructions.
2.4. Analysis of fibrosis
Liver specimens were fixed with 10% formaldehyde and
embedded in paraffin. Tissue sections were mounted on slides,
and Azan staining was performed to analyze the extent of
fibrosis. After establishing a background for each micrograph,
the number of pixels showing a blue color (stained collagen
fibers) was determined with Scion Image (National Institutes ofHealth, Bethesda, MD), and the percentage of fibrosis in the
liver was calculated as the ratio of the blue-colored area to the
total area of the liver.
2.5. Isolation of hepatocytes and assay of viability
Hepatocytes were isolated from rats by perfusion of the liver
with collagenase (Seglen, 1976). The cells were cultured in
William's medium E containing 1 nM insulin, 1 nM dex-
amethasone, and 10% fetal bovine serum. The cells were seeded
onto a dish at 1×105 cells/cm2 in the absence or presence of
fucoidan at 0, 0.3, 0.5, and 1.0 mg/ml. After 6 h of treatment
with fucoidan, CCl4 was added to the cells at 1 mM. After 3 h,
the viability of the cells was assayed by staining with Trypan
blue.
2.6. Isolation of hepatic stellate cells and assay of viability
Hepatic stellate cells were isolated from rat livers by
perfusion with collagenase and pronase, followed by centrifu-
gation on a Nycodenz cushion as described previously (Kawada
et al., 1993). The cells were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% fetal bovine serum.
The cells were then seeded onto a dish at 5×105 cells/cm2 and
then treated with fucoidan at 0, 0.3, 0.5, and 1.0 mg/ml for 24
and 48 h. The viability of the cells was determined by
mitochondrial conversion of 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (Mosmann, 1983). The viability
of the cells was calculated compared to cells at 0 h (i.e., prior to
treatment with fucoidan).
3. Results
3.1. Effect of fucoidan on acute liver injury
We first examined the effect of fucoidan on acute liver failure
induced by single injection of CCl4. Intraperitoneal injection of
mice with CCl4 increased biochemical markers of liver injury.
Specifically, 24 h after injection of CCl4, serum AST and ALT
had increased from 125 to 707 and from 21 to 752 karumen
unit/ml, respectively (Fig. 1). Intravenous administration of
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and 214 karumen unit/ml, respectively, at 25 mg/kg fucoidan).
Notably, injection of 50 mg/kg fucoidan restored serum AST
and ALT to normal levels (77 and 67 karumen unit/ml,
respectively). Together, these results indicate that fucoidan is a
potent inhibitor of acute CCl4-induced liver injury.
3.2. Effect of fucoidan on chronic liver injury
To evaluate the effect of fucoidan on chronic liver injury, we
continuously administered CCl4 to mice twice a week for
8 weeks. Serum AST and ALT levels increased from 149 to 433
and from 101 to 568 karumen unit/ml, respectively (Fig. 2A).
Azan staining revealed that collagen accumulated in the liver,
indicating the onset of liver fibrosis (Fig. 2B). Indeed, the
fibrotic area in the liver increased from 1.9% to 14.8% of theFig. 2. Effect of fucoidan on CCl4-induced chronic hepatic injury. Mice were
injected orally with CCl4 (0.3 ml/kg body weight) and intravenously with
fucoidan (50 mg/kg body weight) twice a week for 8 weeks. (A) Blood was
recovered for determination of serum AST (open column) and ALT (slashed
column). Results indicate are means±S.D. (n=4). (B) Livers were recovered,
sectioned, and stained with Azan. Blue and red areas correspond to fibrotic
and normal regions, respectively. (C) The ratio of the fibrotic blue area to the
blue and red area of the liver was calculated from the sections using NIH
Scion Image. The calculation was performed on five images. Results represent
means±S.D. (n=4).
Fig. 3. Effect of fucoidan on CCl4-treated hepatocytes and hepatic stellate cells.
(A) Effect of fucoidan on CCl4-induced cell death in hepatocytes. Hepatocytes
were treated with CCl4 (1.0 mg/ml) in the absence or presence of fucoidan at the
indicated concentration for 3 h. Viable cells were counted by Trypan blue
staining. Results represent means±S.D. (n=4). (B) Effect of fucoidan on growth
of hepatic stellate cells. Hepatic stellate cells were treated with fucoidan at the
indicated concentration for 24 and 48 h. The viability of the cells was assayed by
mitochondrial conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide. The growth ratio was calculated as a percentage of the viability at
0 h. Results represent means±S.D. (n=4).whole liver (Fig. 2C). The elevation of AST and ALT levels was
significantly reduced by administration of fucoidan (from 433
to 265 and from 568 to 238 karumen unit/ml, respectively;
Fig. 2A). The increase in fibrotic area induced by CCl4 was also
attenuated by fucoidan (from 14.8% to 4.3%; Fig. 2C).
Together, these findings show that fucoidan may be useful for
treatment of hepatic fibrosis in chronic liver injury.
3.3. Effect of fucoidan on hepatocytes and stellate cells
As described above, our preliminary results indicated that
fucoidan may be useful for the treatment of hepatic fibrosis.
During the initiation of hepatic fibrosis, hepatocytes release a
paracrine factor that stimulates hepatic stellate cell growth,
leading to the damage of hepatocyte membranes (Gressner,
1995; Gutierrez-Reyes et al., 2007). Therefore, to determine
how fucoidan prevents liver injury, we evaluated its effects on
hepatocytes and hepatic stellate cells. As shown in Fig. 3A,
treatment of hepatocytes with CCl4 (1 mM) reduced their
viability to 63.3% of control (untreated) cells. In addition,
fucoidan dose-dependently reduced CCl4-induced cell death,
with complete prevention of cell death at 1 mg/ml. Alone,
fucoidan did not show any cytotoxicity at 1.0 mg/ml in
hepatocytes (data not shown). CCl4-induced cell death was not
inhibited by pre-incubation of CCl4 with fucoidan (data not
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CCl4-induced cell death is not due to absorption of CCl4 by
fucoidan. In contrast, the viability of hepatic stellate cells was
reduced to 26.4% of the control by a 48-h treatment with
1.0 mg/ml fucoidan (Fig. 3B). Thus, both the protective effects
of fucoidan against CCl4-induced cell death in hepatocytes and
its cytotoxicity to hepatic stellate cells might contribute to its
anti-fibrotic activity.
4. Discussion
Fucoidan, the sulfated polysaccharides of brown algae,
contains L-fucose residues as the main sugar constituent along
with sulfate esters. Although fucoidan is known to have many
biological activities, including anti-coagulant, anti-thrombosis,
anti-inflammatory, anti-liver failure, and anti-tumor activities
(Boisson-Vidal et al., 1995; Berteau and Mulloy, 2003; Saito
et al., 2006), this is the first investigation of its anti-fibrotic
activity. Our results show for the first time that fucoidan can
reduce hepatic fibrosis in an animal model.
Studies in animal models of hepatic fibrosis show that
extracellular matrix components accumulate in interstitial
regions of the liver around central veins or in the portal tracts.
Normally, hepatic stellate cells exist in a quiescent state, but
they become activated following liver injury. These activated
hepatic stellate cells are primarily responsible for the excess
production of extracellular matrix (Senoo et al., 1998). Thus,
reduction of extracellular matrix production by activated
hepatic stellate cells is crucial for the prevention of fibrogenesis.
Damage to hepatocytes is the primary and continuing factor
leading to hepatic stellate cell activation. Components released
from the damaged cells, including lipid peroxides and reactive
oxygen species, activate Kupffer cells in the liver, leading to
their secretion of transforming growth factor-β (Tsukamoto,
1999). These pro-fibrogenic factors activate hepatic stellate
cells, which results in liver fibrosis. Here, we showed that
treatment of hepatocytes with fucoidan attenuates CCl4-induced
cell death.
Fucoidan has been reported to interact with transforming
growth factor-β and to scavenge reactive oxygen species
(Boisson-Vidal et al., 1995; McCaffrey et al., 1994; Xue et al.,
2001). CCl4 elevates serum transforming growth factor-β levels
and acts as a hepatotoxin by inducing the production of reactive
oxygen species (Weiler-Normann et al., 2007). In agreement
with this, we have found that administration of fucoidan reduces
CCl4-induced lipid peroxidation (data not shown). Taken
together, our results suggest that the anti-fibrogenic activity of
fucoidan is due, at least in part, to attenuation of hepatic stellate
cell activation by inhibition of transforming growth factor-β
and/or by scavenging of reactive oxygen species, which can
suppress the cascade of events that leads to hepatic stellate cell
activation.
Hepatocyte injury is thought to promote fibrosis, leading to
the release of activators from Kupffer cells. In contrast, hepatic
stellate cell apoptosis is thought to be essential for the
resolution phase of fibrosis (Canbay et al., 2002; Song et al.,
2003; Iredale, 2001; Iredale et al., 1998; Issa et al., 2001). Thus,a compound that can prevent hepatocyte injury and/or induce
the death of hepatic stellate cells should be useful for the
treatment of hepatic fibrosis. In the current studies we showed
that fucoidan reduces the growth of hepatic stellate cells and
that it can protect hepatocytes from injury. We also found that
the fucoidan-treated hepatic stellate cells were stained with
annexin V, a marker of apoptosis (data not shown). Taken
together, these findings suggest that fucoidan may be useful for
treating hepatic fibrosis.
Most studies on fucoidan have used a commercially
available crude extract from F. vesiculosus, and we used the
crude fucoidan in the current study. Fucoidan contains
heteropolysaccharides of various kinds besides those consist-
ing predominantly of sulfate and fucose (Nishino et al.,
1994). Patel et al. found that crude commercial fucoidan was
more active than the purified fucoidan at inhibiting the
proliferation of vascular smooth muscle cells, and then they
speculated that a specific structure in the crude fucoidan may
mediate its biological activities (Patel et al., 2002). Indeed,
the content of the sulfated groups in fucoidan determines its
anti-proliferative and anti-coagulant activities in fibroblasts
(Haroun-Bouhedja et al., 2000). The biological activities may
differ among the various structures of pure fucoidan as well
as the different components of crude fucoidan. Identification
of the structures of fucoidan that protect hepatocytes from
hepatotoxins and that inhibit hepatic stellate cell growth is
needed for the development of fucoidan as an anti-fibrotic
agent.
In summary, we found that fucoidan prevents hepatocyte cell
death and induces the death of hepatic stellate cells in an animal
model of hepatic fibrosis. Future studies will examine the
molecular mechanisms of fucoidan in hepatocytes and hepatic
stellate cells. This is the first report that fucoidan has anti-
fibrotic activity and that it is a promising lead for the develop-
ment of anti-fibrotic agents. Identification of the molecular
target and the active structure of fucoidan may lead to the
development of novel anti-fibrotic agents.
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